- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01129154
Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) (PASCE)
An Open Label Multicentric Phase II Study of Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)
Squamous Cell Carcinoma (SCC) is one of the most common malignancies in caucasian population. The effect of the immune system on the development of skin tumors has been demonstrated in transplant patients taking immunosuppressive agents (65 fold risk increase). It has been reported that activation of EGFR and RAS signaling pathways play an important role in disease progression maybe through downregulation of the immune system.
The investigators want to treat unresectable SCC patients with an antibody against EGFR (Vectibix®, panitumumab). This antibody induces tumor regression in metastatic colorectal cancer and has been approved as single agent for this indication.
The investigators want to measure the response rate but also analyze the modification of expression profile of some key proteins involved or supposed to be involved in the signaling pathways of EGFR and in the regulation of the immune system. Chemokines such as CCL27 have been shown to play a critical role in the skin-associated immune response by regulating T cell homing. Pivarcsi et al have reported that downregulation of CCL27 is mediated by activation of EGFR/RAS/MAPK signaling pathways.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicentric study of 17 patients with skin squamous cancer cell.
Eligible patients should not be suitable for immediate surgery. If they have only one tumor, it should be greater than 3 cm2 in order to allow multiple biopsies.
Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
Patients will be assessed at baseline, at week 6 and then every 12 weeks till progression. In addition to clinical examination, evaluation tools will include photography and CT-scan, MRI or PET-scan.
Skin and tumor biopsies will be performed during first cycle at baseline and at days 2, 4, 8, 43, 85. Blood collections for translational research will be done during first cycle at baseline and at days 2, 4, 8,15, 43, 85. Blood collection for hematology and chemistry assessment will be done each 4weeks.
Patients presenting with a stable disease or a tumor response at week 12 will be eligible for maintenance cycles consisting in an infusion of panitumumab every 2 weeks till progression.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Baurain Jean-François, MD, PhD
- Phone Number: +32 2 7645427
- Email: jean-francois.baurain@uclouvain.be
Study Contact Backup
- Name: Duquenne Aline, MSc
- Phone Number: +32 2 7645427
- Email: aline.duquenne@uclouvain.be
Study Locations
-
-
-
Bruxelles, Belgium, 1200
- Recruiting
- Cliniques Universitaires Saint-Luc Université Catholique de Louvain
-
Contact:
- Baurain Jean-Francois, Md,PhD
- Phone Number: +32 2 7645427
- Email: jean-françois.baurain@uclouvain.be
-
Contact:
- Duquenne Aline, MSc
- Phone Number: +32 2 764 5427
- Email: aline.duquenne@uclouvain.be
-
Mont Godinne, Belgium, 5530
- Recruiting
- Cliniques Universitaires UCL
-
Contact:
- Kerger Joseph, MD, PhD
- Phone Number: +32 81423328
-
Ottignies, Belgium, 1340
- Recruiting
- Cliniques Saint-Pierre
-
Contact:
- Duck Lionel, MD
- Phone Number: +32 10414953
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Patient with histologically confirmed diagnosis of SCC.
- Patient must not be candidate to direct curative surgery.
- Tumor evaluation by photography with a ruler and CT-scan, MRI or PET-scan must be performed before enrollment.
- Age ≥ 18 years.
- Karnofsky Performance status (KPS) ≥70.
Normal laboratory values:
- Platelet count ≥100x103/μL
- Leucocyte count ≥ 3x103/μL
- Hemoglobin ≥ 9 g/dL
- ASAT and ALAT ≤ 2.5xUNL
- Serum creatinine ≤1.5xUNL
- Total bilirubin ≤ 1.5xUNL
- Magnesium ≥ Lower Normal Limit (LLN)
- Calcium ≥ Lower Normal Limit (LLN)
- Patient should agree to perform biopsies and blood collections for translational research.
- Signed informed consent from the patient or legal representative must be obtained.
Exclusion criteria
- Clinically significant cardiovascular disease (including cardiac insufficiency NYHA grade III and IV, unstable angina, arrythmia, myocardial infarction, symptomatic congestive heart failure)in the past 12 months before enrollment.
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- No prior chemotherapy.
- Prior anti-EGFR therapy.
- Radiation within four weeks prior to trial entry.
- Subject pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment.
- Subject (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months after the end of treatment.
- The patient has (or has had) previous or concomitant malignancies at other sites within last 5years, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: panitumumab
Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
|
Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: via imaging every 12 weeks
|
To measure the efficacy of Panitumumab for SCC in terms of Overall Response Rate (ORR).
Overall Response Rate (ORR) is defined as the sum of complete and partial tumour responses seen, divided by the total number of evaluable patients.
|
via imaging every 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety profile of panitumumab in SCC
Time Frame: at each visit
|
Proportion of all adverse events will be reported.
CTC scale 3.0 will be used with the exception of skin- or nail-related toxicities, which must be graded using CTC version 3.0 with modifications (Appendix E).
Patients will be followed for safety until closure of study.
|
at each visit
|
Time to treatment failure (TTF)and Time to treatment progression TTP
Time Frame: via imaging, every 12 weeks
|
Time to treatment failure (TTF) is defined as the time from date of first dose of study medication to first occurrence of any following event : documentation of objective tumor progression, toxicities requiring prematurely stop of treatment or death.
TTF will be calculated according to the Kaplan-Meier technique.
Time to Progression will also be calculated.
Subjects without evidence of progression at the end of follow up will be considered as censored.
|
via imaging, every 12 weeks
|
To measure the duration of response.
Time Frame: via imaging, every 12 weeks
|
Duration of overall response will be measured according RECIST guidelines version 1.1 Duration of response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study).
|
via imaging, every 12 weeks
|
To explore the gene expression profiles in SCC under panitumumab treatment (i.e CCL27, EGFR,…).
Time Frame: Skin and tumor biopsies will be performed at baseline and at days 2, 4, 8, 43, 85. Blood will be collected at baseline and at days 2, 4, 8, 43, 85
|
Results will be presented as proportion of each expression type.
|
Skin and tumor biopsies will be performed at baseline and at days 2, 4, 8, 43, 85. Blood will be collected at baseline and at days 2, 4, 8, 43, 85
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Baurain Jean-Francois, Md,PhD, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Luc 09-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Squamous Cell
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditionsCanada, United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingAdvanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell CarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingLocally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell CarcinomaUnited States
-
Baptist Health South FloridaRegeneron PharmaceuticalsWithdrawnSquamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell CarcinomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZeneca; Brooklyn ImmunoTherapeutics, LLCActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell CarcinomaUnited States
-
UNC Lineberger Comprehensive Cancer CenterMayo Clinic; National Institute of Dental and Craniofacial Research (NIDCR)RecruitingCarcinoma, Squamous Cell | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell CarcinomaUnited States
Clinical Trials on infusions of Panitumumab
-
Stanford UniversityCompleted
-
St. Petersburg State Pavlov Medical UniversityActive, not recruitingHematologic MalignancyRussian Federation
-
University Hospital, BrestRoche ChugaiCompletedPolymyalgia RheumaticaFrance
-
Jinnah HospitalJohns Hopkins UniversityCompletedCorona Virus InfectionPakistan
-
Belarusian Research Center for Pediatric Oncology...RecruitingAcute Myeloid LeukemiaBelarus
-
Indiana UniversityIndiana University HealthCompletedCrohn's Disease | Ulcerative Colitis | Protein MetabolismUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedAcute Lymphoblastic Leukemia | Complete Hematologic Remission (CHR) | Persistent/Recurrent Minimal Residual Disease (MRD)Italy
-
The University of New South WalesCompletedUlcerative Colitis | Inflammatory Bowel DiseaseAustralia
-
Université Catholique de LouvainNot yet recruiting
-
PfizerCompleted